Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) have earned an average rating of “Strong Sell” from the nine analysts that are covering the firm, Marketbeat reports. Five investment analysts ...

Galapagos NV (NASDAQ:GLPG) received FDA's IND clearance to begin clinical studies in the US for their CD19 CAR-T program, GLPG5101. The company reported strong clinical data from the ATLANTA study ...

Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on ...

Good day and thank you for standing by. Welcome to the Galapagos Full Year 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

In a report released today, Judah Frommer from Morgan Stanley maintained a Sell rating on Galapagos (GLPG – Research Report), with a price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital.

Barclays analyst Emily Field maintained a Sell rating on Galapagos (0JXZ – Research Report) today and set a price target of €22.00. The ...